Premium
Role of asymmetrical dimethylarginine in the progression of renal disease
Author(s) -
Raptis Vasileios,
Kapoulas Stergios,
Grekas Dimitrios
Publication year - 2013
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2012.01659.x
Subject(s) - asymmetric dimethylarginine , medicine , disease , nitric oxide , kidney disease , endothelial dysfunction , renal function , fibrosis , endocrinology , arginine , amino acid , biochemistry , biology
Raptis V and colleagues provide an in‐depth review on the pathomechanism of the role of ADMA in the progression of chronic kidney disease. They summarize evidence from animal and human studies showing that ADMA is in fact likely to be more than just a marker of progression and assert that intracellular levels of ADMA, generally much higher than plasma levels, potentially mediate kidney progression initiated by other factors such as high blood pressure, dyslipidemia and hyperglycaemia. From this perspective, targeted therapy to reduce ADMA levels including inhibitors of DDAH, or blocking the transporter protein related to intracellular entry of arginine for production of ADMA could potentially retard CKD progression.